Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

Etanercept may not prevent alopecia areata from coming back.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Tofacitinib might be used to treat hair loss.

Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.

The treatment was not recommended due to limited effectiveness and significant side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib treatment is used for teenagers with alopecia areata.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Pexidartinib often causes liver issues and fatigue, especially in women.

ITK inhibitors may effectively treat alopecia areata.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.